PI3K signaling pathway in normal B cells and indolent B-cell malignancies
G Pongas, BD Cheson - Seminars in oncology, 2016 - Elsevier
In chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs), B-cell receptor
signaling leads to activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Idelalisib, a
PI3Kδ inhibitor was approved in 2014 by the US Food and Drug Administration (FDA) in
combination with rituximab for the treatment of patients with CLL for whom single-agent
rituximab would be considered appropriate and as a single agent for patients with relapsed
small lymphocytic lymphoma (SLL) and relapsed follicular lymphoma (FL). Following its …
signaling leads to activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Idelalisib, a
PI3Kδ inhibitor was approved in 2014 by the US Food and Drug Administration (FDA) in
combination with rituximab for the treatment of patients with CLL for whom single-agent
rituximab would be considered appropriate and as a single agent for patients with relapsed
small lymphocytic lymphoma (SLL) and relapsed follicular lymphoma (FL). Following its …